Hogan Lovells advised Mind Medicine Inc. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), completed its underwritten public offering of 9,285,511 common shares, without value, at an offering...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on the deal. Perspective Therapeutics (NYSE AMERICAN: CATX) has completed an underwritten offering of 51,515,880 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Hogan Lovells guided Optinose, Inc. on the deal. Optinose, Inc. (NASDAQ:OPTN) has completed a registered direct offering of approximately US$55 million of its common stock and...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Mind Medicine on the deal. Clinical stage biopharmaceutical company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), completed its underwritten offering of 16,666,667 common shares,...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on a series of strategic transactions. Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has completed a series of strategic transactions with Lantheus Holdings (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised EyePoint Pharmaceuticals on its offering. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) closed its US$230 million follow-on public offering of 13,529,411 shares of common stock...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Soliton on the deal. Allergan Aesthetics, an AbbVie company, will acquire Soliton and RESONIC, its Rapid Acoustic Pulse device, for approximately US$550 million....
You must be a Standard 1 Year member to access this content.
Hogan Lovells has advised EyePoint Pharmaceuticals, Inc. on the deal. Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Among other uses, this...
You must be a Standard 1 Year member to access this content.
